feed,title,long_url,short_url
Benzinga,"After Second Look Oncopeptides' Melflufen Wins Head-To-Head Myeloma Trial, But Difference In OS Triggers FDA Hold",https://benzinga.com/general/biotech/21/07/21893915/after-second-look-oncopeptides-melflufen-wins-head-to-head-myeloma-trial-but-difference-in-os-tri,https://j.mp/2UvIw4G
